Thyroglobulin Flare Response After Radioiodine Ablation in 2 Patients With Differentiated Thyroid Cancer

2015 ◽  
Vol 40 (5) ◽  
pp. 421-422
Author(s):  
James F. Tsang ◽  
Daniel P. Levin ◽  
William D. Leslie
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Ablation ◽  
Flare Response

scholarly journals The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer

2021 ◽  
Author(s):  
Domenico Albano ◽  
Francesco Dondi ◽  
Valentina Zilioli ◽  
Maria Beatrice Panarotto ◽  
Alessandro Galani ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Treatment Response ◽  
Differentiated Thyroid Cancer ◽  
Hashimoto Thyroiditis ◽  
Prognostic Impact ◽  
Intermediate Risk ◽  
Excellent Response ◽  
Radioiodine Ablation ◽  
One Year

Abstract Objective The baseline treatment of differentiated thyroid cancer (DTC) consists of thyroidectomy followed by postoperative risk-adapted radioiodine therapy (RAIT) when indicated. The choice of most appropriate RAI activities to administer with the aim to reach an efficient remnant ablation and reduce the risk of recurrence is yet an open issue and the detection of basal factors that may predict treatment response seems fundamental. The aim of this study was to investigate the potential role of Hashimoto thyroiditis (HT) in predicting 1-year and 5-year treatment response after RAIT and prognosis. Methods We retrospectively included 314 consecutive patients (174 low-risk and 140 intermediate-risk) who received thyroidectomy plus RAIT. One-year and 5-year disease status was evaluated according to 2015 ATA categories response based upon biochemical and structural findings. Results HT was reported histopathologically in 120 patients (38%). DTC patients with concomitant HT received a higher number of RAITs and cumulative RAI activities. Initial RAIT reached an excellent response in 63% after one year and 84% after 5 years. The rate of excellent response one year and 5-year after first RAIT was significantly lower in HT groups, compared to not HT (p < 0.001). Instead, HT did not have a prognostic role considering PFS and OS; while stimulate thyroglobulin (sTg) at ablation was significantly related to survival. Conclusions HT may affect the efficacy of RAIT in low to intermediate risk DTC, particularly reducing the successful rate of excellent response after RAIT. Instead, HT did not have a prognostic impact such as stimulated sTg.

scholarly journals Comparison of Thyroglobulin Concentrations Measured by Two Immunoradiometric Assay

2020 ◽  
Vol 21 (2) ◽  
pp. 121-125
Author(s):  
Vesna Ignjatovic ◽  
Milovan Matovic ◽  
Vladimir Vukomanovic
Keyword(s):  
Thyroid Cancer ◽  
Statistical Analysis ◽  
Differentiated Thyroid Cancer ◽  
Immunoradiometric Assay ◽  
Serum Thyroglobulin ◽  
Specific Test ◽  
Radioiodine Ablation ◽  
Assay Methods ◽  
Positive Correlation Coefficient ◽  
Good Agreement

AbstractCirculating thyroglobulin measurements is a highly specific test in the management of patients affected by differentiated thyroid cancer after total thyroidectomy, followed by radioiodine ablation. The aim of our study was to compare two thyroglobulinimmunoradiometric assays (INEP, Serbia and Cisbio Bioassays, France). Study included 42 patients of both genders with DTC. The subjects were on suppres¬sive doses of levothyroxine and followed up. Results showed concordance between the two assay methods for determining serum thyroglobulin for 39 (92.85%) patients. Statistical analysis showed that there was a direct correlation between two IRMA tests, with a positive correlation coefficient r=0.613 (p 0.05). We concluded that there is good agreement between the two thyroglobulin assays compared in this study.

scholarly journals Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer

2018 ◽  
Vol 7 (4) ◽  
pp. 218-224 ◽  
Author(s):  
Germán A. Jimenez Londoño ◽  
Ana Maria Garcia Vicente ◽  
Julia Sastre Marcos ◽  
Francisco Jose Pena Pardo ◽  
Mariano Amo-Salas ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Low Dose ◽  
Low Risk ◽  
Radioiodine Ablation

scholarly journals Early post-treatment risk stratification of differentiated thyroid cancer: comparison of three high-sensitive Tg assays

2018 ◽  
Vol 178 (1) ◽  
pp. 75-82 ◽  
Author(s):  
Luca Giovanella ◽  
Mauro Imperiali ◽  
Frederik A Verburg ◽  
Pierpaolo Trimboli
Keyword(s):  
Thyroid Cancer ◽  
Diagnostic Performance ◽  
Differentiated Thyroid Cancer ◽  
Receiver Operating Characteristics ◽  
Operating Characteristics ◽  
Serum Samples ◽  
Treatment Risk ◽  
Radioiodine Ablation ◽  
Highly Sensitive ◽  
Over Time

ObjectiveTo assess the diagnostic performance of three high-sensitive assays in a cohort of TgAb-negative and TgAb-positive differentiated thyroid cancer (DTC) patients.DesignRetrospective study on prospectively selected DTC patients.MethodsSerum samples from 154 DTC patients were obtained 6–12 months after radioiodine ablation and tested by Beckman, Roche, BRAHMS Tg and TgAb assays, respectively. Receiver operating characteristics curves for Tg were plotted using outcome over time as benchmark and assay-specific Tg thresholds were obtained for TgAb-negative and TgAb-positive patients.ResultsThe frequency of positive TgAb was 21, 20 and 20% for Beckman, Roche and BRAHMS, respectively. In TgAb-negative patients, clinical sensitivities and specificities of 100% and 85–95%, respectively, were observed across all assays. In TgAb-positive patients, clinical sensitivities and specificities of 80–100% and 92–96%, respectively, were observed using lower thresholds than in patients without TgAb.ConclusionsAdopting appropriate thresholds, lower than those for TgAb-negative patients, is possible to reliably follow TgAb-positive patients using highly sensitive Tg assays.

Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer

2014 ◽  
Vol 37 (8) ◽  
pp. 709-714 ◽  
Author(s):  
Alberto S. Tresoldi ◽  
Laura F. Sburlati ◽  
Marcello Rodari ◽  
Mink Schinkelshoek ◽  
Michela Perrino ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Ablation

scholarly journals Redox parameters in blood of thyroid cancer patients after the radioiodine ablation

2017 ◽  
Vol 32 (4) ◽  
pp. 358-365
Author(s):  
Vera Spasojevic-Tisma ◽  
Milovan Matovic ◽  
Olgica Mihaljevic ◽  
Snezana Zivancevic-Simonovic ◽  
Marija Jeremic ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Reduced Glutathione ◽  
Thiobarbituric Acid ◽  
Oxygen Species ◽  
Thiobarbituric Acid Reactive Substances ◽  
Radioiodine Ablation

The radioactive iodine (131I) ablation is a well-accepted treatment modality for differentiated thyroid cancer patients. Unfortunately, the radiation induces the oxidative stress and damages cells and tissues, simultaneously activating the mechanisms of antioxidative defense. Since the mechanisms of those processes are not completely known, we wanted to examine the changes in the most important reactive oxygen species and antioxidative components, as well as their correlation and significance for lipid peroxidation. Our results showed that the level of thiobarbituric acid reactive substances was increased during the first 30 days after the radiotherapy. Among antioxidant components, superoxide dismutase was increased in the 3rd and 30th day; catalase in 7th and reduced glutathione in 3rd and 7th day after the radiotherapy. As regards the prooxidants, the reduction of hydrogen peroxide (H2O2) was recorded in 7th and 30th day, and superoxide anion radical (O?-) was unchanged after the exposure to 131I. These results indicate that differentiated thyroid cancer patients are under constant oxidative stress despite the observed increase in antioxidative and reduction in prooxidative parameters. The understanding of these early processes is important since their progress determines the latter effects of 131I therapy.

Sign in / Sign up

Export Citation Format

Share Document